Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
1.970
-0.080 (-3.90%)
At close: Jun 27, 2025, 4:00 PM
2.030
+0.060 (3.05%)
After-hours: Jun 27, 2025, 7:20 PM EDT
Vistagen Therapeutics Revenue
In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%. Vistagen Therapeutics had revenue of $-15.00K in the quarter ending March 31, 2025, a decrease of -107.61%.
Revenue (ttm)
$486.00K
Revenue Growth
-54.32%
P/S Ratio
130.89
Revenue / Employee
$8,526
Employees
57
Market Cap
57.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
| Mar 31, 2024 | 1.06M | 1.29M | -568.72% |
| Mar 31, 2023 | -227.00K | -1.34M | -120.47% |
| Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
| Mar 31, 2021 | 1.09M | - | - |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VTGN News
- 3 days ago - Vistagen Appoints Elissa Cote as Chief Corporate Development Officer - Business Wire
- 10 days ago - Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 16 days ago - Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 - Business Wire
- 26 days ago - Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year - Business Wire
- 4 weeks ago - Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - Business Wire
- 5 weeks ago - Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - Business Wire
- 2 months ago - Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Business Wire